Involvement of autophagy in diosgenin‑induced megakaryocyte differentiation in human erythroleukemia cells

Mol Med Rep. 2021 Nov;24(5):746. doi: 10.3892/mmr.2021.12386. Epub 2021 Aug 30.

Abstract

Natural agents have been used to restart the process of differentiation that is inhibited during leukemic transformation of hematopoietic stem or progenitor cells. Autophagy is a housekeeping pathway that maintains cell homeostasis against stress by recycling macromolecules and organelles and plays an important role in cell differentiation. In the present study, an experimental model was established to investigate the involvement of autophagy in the megakaryocyte differentiation of human erythroleukemia (HEL) cells induced by diosgenin [also known as (25R)‑Spirosten‑5‑en‑3b‑ol]. It was demonstrated that Atg7 expression was upregulated from day 1 of diosgenin‑induced differentiation and was accompanied by a significant elevation in the conversion of light chain 3 A/B (LC3‑A/B)‑I to LC3‑A/B‑II. Autophagy was modulated before or after the induction of megakaryocyte differentiation using 3‑methyladenine (3‑MA, autophagy inhibitor) and metformin (Met, autophagy initiation activator). 3‑MA induced a significant accumulation of the LC3 A/B‑II form at day 8 of differentiation. It was revealed that 3‑MA had a significant repressive effect on the nuclear (polyploidization) and membrane glycoprotein V [(GpV) expression] maturation. On the other hand, autophagy activation increased GpV genomic expression, but did not change the nuclear maturation profile after HEL cells treatment with Met. It was concluded that autophagy inhibition had a more prominent effect on the diosgenin‑differentiated cells than autophagy activation.

Keywords: 3‑methyladenine; autophagy; diosgenin; human erythroleukemia cells; megakaryocyte differentiation.

MeSH terms

  • Apoptosis / drug effects
  • Autophagy / drug effects*
  • Autophagy / genetics
  • Cell Differentiation / drug effects*
  • Cell Line
  • Diosgenin / pharmacology*
  • Humans
  • Leukemia, Erythroblastic, Acute / metabolism*
  • Megakaryocytes / metabolism*
  • RNA, Messenger / metabolism

Substances

  • RNA, Messenger
  • Diosgenin

Grants and funding

The present study was funded in part by the Ministry of Higher Education, Research and Innovation by the New Aquitaine Regional Council and by the Lebanese University of Beirut (Beirut, Lebanon).